InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 -0.001 (-20%)+
Announcement
Release
19 Aug 2026 11:33AM
Price at Release
$0.005
Full Release
download
Summary
Percheron Therapeutics Limited's annual report for the year ending 30 June 2026 highlights a financial overview with a net loss of $4,791,745, significant research and development expenditures, and share-based payment expenses. The company saw a decline in issued capital and did not declare any dividends. Key developments include issuing new employee stock options and entering a strategic licensing agreement with Hummingbird Bioscience for a monoclonal antibody therapy. These financial and strategic actions are aligned with the company's ongoing development efforts in the biotechnology sector.
Key Points
  • Percheron Therapeutics Limited reported a net loss of $4,791,745 for the financial year ending 30 June 2026.
  • The company recognized $353,379 in share-based payment expenses for the year.
  • Issued capital at 30 June 2026 was $63,417,726, down from $112,048,298 the previous year.
  • Research and Development expenses for the year amounted to $2,087,558.
  • No dividends were paid or declared during the financial year.
  • The company issued 8,100,000 options to employees on 3 July 2026 under its Employee Share Option Plan.
  • Percheron entered into a licensing agreement with Hummingbird Bioscience for HMBD-002, involving an upfront payment of USD $3.0 million and potential milestone payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.